Feature | Heart Valve Technology | May 16, 2016

Moderate Sedation Shows Promise for TAVR Patients

Late-breaker study at SCAI shows less anesthesia may help improve TAVR outcomes

A Medtronic CoreValve TAVR device being deployed under angiographic image guidance.

 

 

May 16, 2016 — The largest observational study of percutaneous transfemoral transcatheter aortic valve replacement (TAVR) demonstrated that moderate sedation use is associated with improved patient outcomes, including lower 30-day mortality and shorter hospital stays, as compared to traditional general anesthesia. This STS/ACC TVT Registry analysis was presented as a late-breaking clinical trial at the 2016 Society for Cardiovascular Angiography and Interventions (SCAI) annual meeting. 

TAVR has become the therapy of choice for patients who are considered at extreme or high-risk for standard open surgical aortic valve replacement, with recent data supporting extension of the therapy into intermediate-risk populations. While general anesthesia has been typically administered during these cases, rates of moderate sedation use for this minimally invasive technique are increasing. 

“TAVR is revolutionary, but the question we asked ourselves is what novel techniques are being employed to make the therapy even better and as noninvasive as possible?” said Jay Giri, M.D., MPH, an assistant professor of cardiovascular medicine in the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and the study’s senior investigator. “Now that we are routinely treating patients without incisions, is moderate sedation a safe and effective option for TAVR?” 

Investigators compared the effectiveness of moderate sedation and general anesthesia use among STS/ACC TVT Registry patients between April 2014 and June 2015. The registry is comprised of all U.S. TAVR patients and elective cases treated via percutaneous transfemoral approach and all were included in the analysis. A total of 10,997 patients were assessed, and of these 1,737 (15.8 percent) received moderate sedation. 

While both patient groups had nearly equal rates of TAVR success (98.4 vs. 98.6 percent, p=0.46), moderate sedation patients experienced lower rates of 30-day mortality (2.92 vs. 4.08 percent, p=0.035), 30-day mortality or stroke (4.8 vs. 6.4 percent, p=0.019), and briefer hospital stays (6+/-10.7 vs. 6.7 +/9.6 days, p<0.0001).  

Importantly, propensity-matched analyses, which accounted for factors known to predict 30-day TAVR mortality, confirmed lower 30-day mortality (2.96 vs. 4.01 percent, p<0.0001) and 30-day mortality or stroke (4.8 vs. 6.36 percent, p<0.0001) among the moderate sedation patients. Nationally, 5.9 percent of moderate sedation patients converted to general anesthesia, which was comparable to the 5.2 percent rate observed at the University of Pennsylvania Health System according to Giri. 

“This compelling data shows that moderate sedation is both safe and effective. While it is important to assess each patient individually, using moderate sedation could result in a better experience and better clinical outcomes for patients,” said Giri. “A broad shift towards moderate sedation for TAVR could have profound implications for care pathways, costs and the future of this technology.” 

Giri reports grants to the institution from St. Jude Medical for service as site co-primary investigator of the PORTICO trial of transcatheter aortic valve replacement. 

 

Read article about the use of conscious sedation for aortic aneurysm repair
 

 

For more information: www. SCAI.org/SCAI2016 

 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Overlay Init